Rhobust technology acquisition

DSM Biologics, a business unit of DSM Pharmaceutical products, has announced that it has reached an agreement for the acquisition of the assets and associated business of the Rhobust technology from Upfront Chromatography A/S.

According to the companies, the technology is capable of performing high titre and high density cell culture processes, which allows for stable expanded bed adsorption chromatography. The cells are separated in one step while capturing the protein/antibody of interest; during the expanded bed adsorption chromatography process the cell suspension passes through the column and the product is adsorbed either on Protein A or on mixed mode ligand beads. This leads to less handling and shorter process times.

In a statement, Karen King, president of DSM Biologics commented, “The acquisition of the Rhobust technology is an important addition to the portfolio of DSM Biologics. The Rhobust technology combined with DSM’s proprietary XD technology will provide an integral package combining high titre, high yield processing with efficient downstream processing leading to lower manufacturing costs.”

As a result of the acquisition, DSM Biologics will gain all rights for the commercialization of the technology in various fields, including the pharma industry.

The technology will lead to further innovation in the downstream processing for the manufacturing of recombinant proteins and antibodies. DSM Biologics will continue to support all existing clients for this technology. The parties have agreed to not disclose financial details.

For more information about this technology visit www.dsm.com